ArticleProbiotics and antimicrobial proteins2019
Study on Antiviral Activity of Two Recombinant Antimicrobial Peptides Against Tobacco Mosaic Virus.
Article in Probiotics and antimicrobial proteins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advanced molecular tools for surveillance and management of tobamoviruses.Frontiers in plant science · 2025Review
- Expression of a novel NaD1 recombinant antimicrobial peptide enhances antifungal and insecticidal activities.Scientific reports · 2024Article
- Thanatin: A Promising Antimicrobial Peptide Targeting the Achilles' Heel of Multidrug-Resistant Bacteria.International journal of molecular sciences · 2024Review
- In Vitro/Vivo Mechanisms of Antibacterial Peptide NZ2114 againstAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides (AMPs) are generally small peptides with less than 50 amino acid residues, which have been considered as the first line of defense system in plants and animals. These small cationic peptides belong to a family of antimicrobials that are multifunctional effectors of innate immunity. The direct antimicrobial activity of AMPs against different bacteria, viruses, fungi, and parasites has been confirmed in different studies. In this study, the antiviral activity of two recombinant AMPs named thanatin and lactoferricin+lactoferrampin was evaluated against Tobacco mosaic virus (TMV) using half-leaf and leaf disk methods under in vivo and in vitro condition, respectively. The obtained result indicated that both recombinant AMPs have shown an antiviral activity against TMV. Compared to the chimeric lactoferricin+lactoferrampin, recombinant thanatin showed a higher rate of antiviral activity against TMV. Three types of effects, including protective, curative, and inactivation, were evaluated during an antiviral activity test. In the present study, the antiviral activity of two recombinant AMPs is represented for the first time: thanatin and chimeric lactoferricin+lactoferrampin against TMV as a viral plant pathogen.
Indexed as
Identifiers
30887308What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.